Physician profile
Mark A Dipillo
NPI 1073583902
$4,004.28
in general payments reported to CMS, 2019-2025
25 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $549 · 2021: $708 · 2022: $111 · 2023: $280 · 2024: $227 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $867.29 | 2019-2021 | |
| Alcon Vision LLC | $814.24 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Ivantis, INC | $324.95 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $323.93 | 2019-2021 | |
| Abbvie INC. | $242.96 | 2022-2025 | Durysta |
| Aerie Pharmaceuticals, INC. | $231.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $217.97 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $210.42 | 2023-2025 | Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $113.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $98.88 | 2019-2021 | |
| Alimera Sciences, INC. | $86.39 | 2019-2021 | |
| Eyepoint US, INC. | $71.43 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $63.20 | 2019 | |
| Omeros Corporation | $59.86 | 2019 | |
| Mallinckrodt Hospital Products INC. | $45.52 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $39.96 | 2022-2024 | Tyrvaya |
| Biotissue Holdings INC. | $33.93 | 2020-2021 | |
| New World Medical,INC. | $23.90 | 2020 | |
| Horizon Therapeutics Plc | $23.87 | 2021 | |
| Tearlab Corp | $23.77 | 2021 | |
| Dompe US, INC. | $23.58 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $23.22 | 2025 | Xdemvy |
| Shire North American Group INC | $21.05 | 2019 | |
| Celularity INC. | $18.96 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$180,066.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dipillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.